CTOs on the Move

AccessOne MedCard

www.accessonemedcard.com

 
AccessOne is a leading provider of flexible, co-branded patient financing solutions. Founded by providers, our solution provides a consumer-focused experience which drives high patient satisfaction for our clients. We have helped over one million consumers afford out-of-pocket medical expenses for health systems nationwide. We offer the most comprehensive platform in the industry with funding models that help more providers and programs that reach more patients. All patients qualify for our program with no credit reporting or negative outcomes.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Rajneesh Kumar
 Chief Technology Officer Profile
Steven VanLanen
 Infrastructure Director, CISO Profile

Funding

AccessOne MedCard raised $225M on 11/19/2019

Similar Companies

Lombart Instrument

Lombart Instrument is a Norfolk, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arnold Dental Supply Inc

Arnold Dental Supply Inc is a Lynnwood, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Premier Medical

Premier Medical is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MD Buyline

MD Buyline is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.